Photopheresis Products Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR (2024 - 2029) | 5.70 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Photopheresis Products Market Analysis
The Photopheresis Products Market is expected to register a CAGR of 5.70% during the forecast period.
The demand for photopheresis treatments is rising globally, driven by a rise in organ transplantations, cutaneous T-cell lymphoma cases, and favorable reimbursement policies.
Such a huge number of organ transplants globally and in developed regions, such as the United States, is anticipated to increase the adoption of photopheresis products in organ transplantations, driving market growth. For instance, according to the US Department of Health & Human Services data published in March 2024, 46 thousand organ transplants were performed in the United States, and 103,223 people were waiting for an organ transplant in 2023. Thus, the increasing prevalence of organ transplants globally directly correlates with the rising demand for photopheresis due to its pivotal role in managing transplant rejection and related complications, thereby boosting market growth.
The increasing geriatric population worldwide is a major driver for the photopheresis products market, as these treatments are often used for age-related autoimmune and organ transplant conditions. For instance, according to the Australian Institutes of Health and Welfare, in March 2024, the rate of burden from rheumatoid arthritis was 1.6 times as high for females compared with males in 2023 (5.3 and 3.3 DALY per 1,000 population, respectively). Thus, the high burden of autoimmune diseases is expected to increase demand for photopheresis as it can suppress this harmful immune response, which is expected to boost market growth over the forecast period.
Additional factors such as the rising healthcare infrastructure, technological advancement, and growing geriatric population are further expected to drive the market for photopheresis products during the forecast period. The key market players' ongoing initiatives in photopheresis, such as the approvals and launch of innovative products, are anticipated to drive the market studied due to increased adoption.
For instance, in August 2022, Ikaria Australia Pty Ltd, a Mallinckrodt Pharmaceuticals company, launched the THERAKOS CELLEX Photopheresis System in the Australian market. The CELLEX instrument performs the extraction, treatment, and reinfusion of white blood cells for an integrated, closed photopheresis procedure. Similarly, in September 2022, a new apheresis unit was opened in the United Arab Emirates in the Sheikh Shakhbout Medical City (SSMC) as a collaboration between Abu Dhabi Health Services Company (SEHA) and Mayo Clinic. Sheikh Shakhbout Medical City widens the treatment scope for diseases, including rare lymphoma of the skin.
Therefore, factors such as rising organ transplantations, rising prevalence of autoimmune diseases, and rising initiatives from key market players are anticipated to drive market growth. However, the low adoption of photopheresis in pediatric patients and a lack of skilled professionals are expected to hamper market growth.
Photopheresis Products Market Trends
Chronic Graft Versus Host Disease (GvHD) is Expected to Hold a Significant Market Share in the Market Studied.
Chronic graft-versus-host disease (GvHD) is a systemic disorder that happens when the graft's immune cells recognize the host as foreign and attack the recipient's body cells. It is a common complication after an allogeneic hematopoietic stem cell transplant (HCT). In GvHD, the recipient's body is attacked by the donated bone marrow or peripheral blood stem cells as they perceive it as foreign.
Extracorporeal photopheresis (ECP) remains one of the subsequent therapeutic choices in the treatment of GvHD, which is expected to drive market growth. According to a study published in Medicine in November 2022, with an overall response rate ranging from 31% to 93% and the maximum efficacy reported for individuals with skin involvement, ECP's effectiveness in treating cGVHD was well-documented. Photopheresis is particularly effective in treating conditions like graft-versus-host disease (GVHD) in stem cell transplants and chronic rejection in solid organ transplants. GVHD occurs when the transplanted immune cells attack the recipient's tissues, and photopheresis can suppress this harmful immune response, which is expected to boost the segment’s growth.
It should be noted that prolonged ECP is typically required for a clear visual result. In addition, according to the study published in the American Society for Transplantation and Cellular Therapy in November 2022, ECP was recognized as an effective immunomodulatory therapy with mild adverse events in GvHD. Such advantages and effectiveness of photopheresis in GvHD are expected to increase its adoption, driving the segment’s growth.
Rising initiatives from the national governments for the implementation of ECP for GvHD are expected to bolster the segment’s growth over the forecast period. For instance, in March 2022, the government of Australia passed a regulation for initial ECP treatment, and continuing ECP treatment was introduced for patients with GvHD following allogeneic hematopoietic stem cell transplantation. Such initiatives are expected to increase the adoption of ECP in GvHD, driving the segment’s growth.
Therefore, the government's rising initiatives and the importance of photopheresis in GvHD are the factors expected to drive the segment’s growth.
North America Holds a Significant Share and Expected to do the Same During the Forecast Period
The factors driving the market in North America include rising organ donations, a strong foothold and rising initiatives of the key market players, and developed healthcare infrastructure.
As the number of organ transplants increases worldwide due to advancements in medical technology and increased donor availability, the demand for supportive therapies like photopheresis also rises. This is because transplant recipients require ongoing management to prevent rejection and maintain the health of the transplanted organ. For instance, according to the Canadian Institute of Health Information, in June 2024, a total of 3,428 organ transplants were performed in Canada in 2023; 83% of transplants used deceased donor organs, and 17% used living donor organs. Such organ transplantations are expected to drive market growth in the region due to the increased adoption of photopheresis products to overcome organ transplant rejection.
Furthermore, rising initiatives from key market players are also expected to drive market growth in the region. For instance, in July 2021, Terumo Blood and Cell Technologies launched a direct offering for physicians to perform extracorporeal photopheresis immunotherapy (ECP) procedures at the patient's bedside.
Terumo Blood and Cell Technologies is a medical technology company that specializes in a portfolio of products, software, and services for blood collection, therapeutic apheresis, and cellular technologies. Such an initiative is expected to increase the adoption of photopheresis products in blood collection and processing, driving market growth.
Moreover, the presence of blood processing centers and advanced apheresis are also some of the main factors ensuring the dominance of the region. Therefore, factors such as rising organ transplantation and rising initiatives from the key market players are expected to drive market growth in the region.
Photopheresis Products Industry Overview
The photopheresis products market is consolidated and consists of a few major players. The prominent players are vigorously collaborating and acquiring other companies to consolidate their market positions worldwide. Some of the companies operating in the market are Haemonetics Corporation, Fresenius Kabi AG, Macopharma, Mallinckrodt Pharmaceuticals, and PIT Medical Systems.
Photopheresis Products Market Leaders
-
Fresenius Kabi AG
-
Macopharma
-
Mallinckrodt Pharmaceuticals
-
PIT Medical Systems
-
Haemonetics Corporation
*Disclaimer: Major Players sorted in no particular order
Photopheresis Products Market News
- February 2024: Mallinckrodt PLC unveiled a poster presentation detailing the results of a comprehensive review and meta-analysis on the effectiveness and safety of extracorporeal photopheresis (ECP) in treating patients with steroid-refractory chronic graft-versus-host disease (SR-cGvHD). The analysis, which drew from 47 studies focusing on the THERAKOS CELLEX Photopheresis System, highlighted that ECP treatment significantly enhanced patients' overall survival (OS), failure-free survival (FFS), and overall response rate (ORR).
- September 2023: Fresenius Kabi introduced a single-needle venous access option for the Amicus Extracorporeal Photopheresis (ECP) System at the 49th annual meeting of the European Society for Blood and Marrow Transplantation (EBMT).
Photopheresis Products Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumption and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Prevalence of Autoimmune Diseases
4.2.2 Increasing Technological Advancements
4.3 Market Restraints
4.3.1 Low Adoption of Photopheresis in Pediatric Patients and Lack of Skilled Professionals
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Open System
5.1.2 Closed System
5.2 By Application
5.2.1 Graft versus Host Disease
5.2.2 Cutaneous T-Cell Lymphoma
5.2.3 Transplant Rejections
5.2.4 Autoimmune Diseases
5.3 By End User
5.3.1 Hospitals
5.3.2 Ambulatory Centers
5.3.3 Other End Users
5.4 By Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Haemonetics Corporation
6.1.2 Fresenius Kabi AG
6.1.3 Macopharma
6.1.4 Mallinckrodt Pharmaceuticals
6.1.5 PIT Medical Systems
6.1.6 Thermo Fisher Scientific
6.1.7 Terumo Corporation
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Photopheresis Products Industry Segmentation
As per the scope of the report, photopheresis (also known as extracorporeal photopheresis [ECP]) is a medical treatment that removes blood through a machine and isolates white blood cells. These isolated white cells are exposed to a medication called 8-methoxy psoralen followed by UVA irradiation before returning the blood to the patient. Photopheresis is used to treat medical conditions such as lung transplant rejection, heart transplant rejection, chronic graft versus host disease (GVHD), and cutaneous T-cell lymphoma (CTCL).
The photopheresis products market is segmented by product type, application, end user, and geography. By product type, the market is segmented into open and closed systems. By application, the market is segmented as graft versus host disease, cutaneous T-cell lymphoma, transplant rejections, and autoimmune diseases. By end user, the market is segmented into hospitals, ambulatory centers, and other end users. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America.
The report offers the value (USD) for the above segments.
| By Product Type | |
| Open System | |
| Closed System |
| By Application | |
| Graft versus Host Disease | |
| Cutaneous T-Cell Lymphoma | |
| Transplant Rejections | |
| Autoimmune Diseases |
| By End User | |
| Hospitals | |
| Ambulatory Centers | |
| Other End Users |
| By Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Photopheresis Products Market Research FAQs
What is the current Photopheresis Products Market size?
The Photopheresis Products Market is projected to register a CAGR of 5.70% during the forecast period (2024-2029)
Who are the key players in Photopheresis Products Market?
Fresenius Kabi AG, Macopharma, Mallinckrodt Pharmaceuticals, PIT Medical Systems and Haemonetics Corporation are the major companies operating in the Photopheresis Products Market.
Which is the fastest growing region in Photopheresis Products Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Photopheresis Products Market?
In 2024, the North America accounts for the largest market share in Photopheresis Products Market.
What years does this Photopheresis Products Market cover?
The report covers the Photopheresis Products Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Photopheresis Products Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Photopheresis Products Industry Report
Statistics for the 2024 Photopheresis Products market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Photopheresis Products analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
